Exciting to be part of this journey!

What books 📚 do you recommend I read in 2022? Check out my 2021 book/podcast choices along with some of my learnings & thoughts on the past year. joaoribas.medium.com/best-of-2021-b…

Here's what my team has been up to in 2021. Record of >US$ 550 million raised by portfolio companies, 5 new investments (biotech) and 2 new companies launched. We also did 2 new investments in bio industrials.

Our inspiring vision on using the power of biology to change the world! youtube.com/watch?v=jATd_I…

Replace your "$ x billion market" slide with a detailed understanding of your clinical indication. See Sara Nayeem's spot-on thread below for what VCs want to know.

Proud to announce the acquisition of our portfolio company @syndesi_tx! It's been super exciting to be part of this journey and to witness the company development over the years 🚀

I'm a big fan and proponent of the "investment highlights" slide! Super helpful to get the bigger picture and convey the message at Partner meetings.

Launching 𝘥𝘦 𝘯𝘰𝘷𝘰 - a Novo Seeds blog on biotech. The first article is about the role of entrepreneurs-in-residence in venture creation, from a VC and EiR perspective. What other topics would you like to read about? Novo Holdings denovo.novoholdings.dk/entrepreneurs-…

📢 Excited to announce our latest Novo Holdings investment - Engimmune Therapeutics - a company pioneering novel TCR-based therapies using a cutting-edge TCR engineering platform 📢 #biotech #VentureCapital

An Experimental Gene Therapy Changed His DNA—And His Hair Color - The Atlantic. $AVRO theatlantic.com/science/archiv…

Wow! Brilliant idea and execution!

Check out the newest feature in Biopharma Dealmakers that selected Asgard Therapeutics platform technology as an innovative gene therapy to reprogram anti-cancer immunity. #Immunotherapy #biopharma nature.com/articles/d4374…

Only Sara Nayeem could make a thread about footnotes that's insightful and helpful to biotech execs.

Here’s the Atlas Venture 2022 Year In Review. This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas youtu.be/LONM9ekseJ4

Top product forecasts for 2023 go.nature.com/3UpqQAX - a new analysis of the expected top-selling products next year Amy Brown @EvaluatePharma, places the immune checkpoint inhibitor Keytruda at the top

Congrats Pereira Lab !!

One of the most exciting uses of large language models is to help us learn more efficiently. Inspiring to see what it can do - a personalized tutor always available! youtube.com/watch?v=hJP5Gq…

If you're in biotech this needs to be on your list every year. Fantastic analysis and review Bruce Booth

San Francisco will be our home base this week as we meet with companies and investment partners from across the globe. We support companies in the US, Europe and Asia, across the life sciences continuum from very early-stage Seed investments, through the Ventures and Growth

Happy to announce the launch of Orbis Medicines! Learn more at orbismedicines.com